Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    "RWJMS" OR "Robert Wood Johnson Medical School" OR "Cancer Institute of New Jersey" OR "CINJ" | Open Studies | "Neoplasms, Unknown Primary"
Show Display Options
Rank Status Study
1 Recruiting Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer or Metastatic Large Cell Neuroendocrine Non-Small Cell Lung Cancer
Conditions: Carcinoma of Unknown Primary Origin;   Extensive Stage Small Cell Lung Carcinoma;   Large Cell Lung Carcinoma;   Neuroendocrine Carcinoma;   Newly Diagnosed Carcinoma of Unknown Primary Origin;   Stage IV Non-Small Cell Lung Cancer
Interventions: Drug: Veliparib;   Other: Placebo;   Drug: Etoposide;   Drug: Cisplatin;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration;   Other: Quality-of-Life Assessment

Indicates status has not been verified in more than two years